MTOR and lymphangioleiomyomatosis: Research has shown [14] that functional loss mutations in tuberous sclerosis complex (TSC) 1 and 2 can be broadly detected in LAM cells, activating the mechanistic target of rapamycin (mTOR) pathway, which also plays a crucial role in B-cell hyperactivation [15].